Patent ID: 8227202

Claim:
A method of diagnosing, prognosing, or determining progression of acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasms in an individual, said method comprising: classifying one or more hematopoietic cells associated with acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasms in said individual by a method comprising: a) subjecting a cell population comprising said one or more hematopoietic cells from said individual to a plurality of modulators in a plurality of cultures, b) characterizing a at least three pathways in one or more cells from said plurality of cultures by determining an activation level of at least one activatable element within the at least three pathways, wherein i) at least two of the pathways being characterized are an apoptosis pathway and a DNA damage pathway, ii) the modulators activate or inhibit one or more of said at least three pathways being characterized, and c) classifying said one or more hematopoietic cells into groups comprising response or non response to therapeutic treatment, or risk of relapse based on said pathways characterization, said classification enabling a decision regarding diagnosis, prognosis or progression of acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasms in said individual, wherein said decision is based on said classification of said cells.